Associated Papers
Pathogenic variants reveal candidate genes for prostate cancer germline testing for men of African ancestry.
Gheybi K et al.
Nature Communications, 2025
Clinical characterization and therapeutic targeting of fusion genes in oncology.
Morand S et al.
Future Oncology (london, England), 2025
Non-Small-Cell Lung Cancers (NSCLCs) Harboring RET Gene Fusion, from Their Discovery to the Advent of New Selective Potent RET Inhibitors: "Shadows and Fogs".
Spitaleri G et al.
Cancers, 2024
Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations.
Wang ZX et al.
Journal of Medicinal Chemistry, 2024
Molecular Basis and Natural History of Medullary Thyroid Cancer: It is (Almost) All in the RET.
Sahakian N et al.
Cancers, 2023
The clinical utility and costs of whole-genome sequencing to detect cancer susceptibility variants-a multi-site prospective cohort study.
Davidson AL et al.
Genome Medicine, 2023
Looking for RET alterations in thyroid cancer: clinical relevance, methodology and timing.
Elisei R et al.
Endocrine, 2023
DrABC: deep learning accurately predicts germline pathogenic mutation status in breast cancer patients based on phenotype data.
Liu J et al.
Genome Medicine, 2022
Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine.
Matrone A et al.
Frontiers in Endocrinology, 2022
Non-small-cell lung cancer: how to manage RET-positive disease.
Andrini E et al.
Drugs in Context, 2022
Precision oncology for RET-related tumors.
Verrienti A et al.
Frontiers in Oncology, 2022
Association between somatic RET mutations and clinical and genetic characteristics in patients with metastatic colorectal cancer.
Yang YZ et al.
Cancer Medicine, 2021
Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development.
Saha D et al.
Journal of Medicinal Chemistry, 2021
Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases.
Moccia M et al.
Scientific Reports, 2021
Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic.
Williams EA et al.
Acta Neuropathologica Communications, 2020
Characterization of novel genetic alterations in salivary gland secretory carcinoma.
Na K et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2020
Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations.
Elisei R et al.
Genes, 2019
Targeted mutation detection in breast cancer using MammaSeq™.
Smith NG et al.
Breast Cancer Research : Bcr, 2019
Drug resistance profiles of mutations in the RET kinase domain.
Liu X et al.
British Journal of Pharmacology, 2018
Pathogenic Mutations in Cancer-Predisposing Genes: A Survey of 300 Patients with Whole-Genome Sequencing and Lifetime Electronic Health Records.
He KY et al.
Plos One, 2016
Elevated level of serum carbohydrate antigen 19.9 as predictor of mortality in patients with advanced medullary thyroid cancer.
Elisei R et al.
European Journal of Endocrinology, 2015
Mutations in 12 known dominant disease-causing genes clarify many congenital anomalies of the kidney and urinary tract.
Hwang DY et al.
Kidney International, 2014
In silico profiling and structural insights of missense mutations in RET protein kinase domain by molecular dynamics and docking approach.
George Priya Doss C et al.
Molecular Biosystems, 2014